Australia Legal Cannabis Market Size, Share, Growth and Forecast, 2025-2035

Prescribed medicinal products and hemp drive steady demand

The Australia legal cannabis market was valued at USD 551.5 million in 2025 and is projected to increase from USD 590.4 million in 2026 to USD 1.08 billion by 2035, registering a CAGR of 6.91% during 2026–2035. Demand comes from adults and children prescribed unapproved medicinal products through doctors and nurse practitioners, and from buyers of hemp foods, seeds and fiber. New South Wales and Australian Capital Territory held the largest regional share, 33.7% in 2025, because the zone has the most people, prescribers and dispensing pharmacies. Queensland and Northern Territory is the fastest-growing region at 7.28% a year, as population growth adds new patients. In turn, the national medicines regulator has reviewed oversight of unapproved products, which points to tighter labeling and packaging standards for sponsors.

Which medicinal and hemp products does the estimate cover?

The estimate measures the value of legally supplied medicinal flower, oils, capsules, vaporizer cartridges and other formulations dispensed on prescription in Australia, plus licensed industrial hemp products such as hemp seed foods, oils and fiber. It counts sales through community pharmacies, specialist dispensing pharmacies and hemp retail and trade channels.

The estimate excludes illegal supply, adult-use sales, which are not legal nationally, clinic consultation fees, vaporizer devices sold on their own and exports. The value chain runs from licensed growers, importers and manufacturers through product sponsors and wholesalers to pharmacies, hemp retailers and end users.

Flower, pain care and pharmacy dispensing lead value

Why does medicinal flower lead product value?

Based on product type, the market is categorized into medicinal flower, medicinal formulations and industrial hemp products. Medicinal Flower led with a 52.0% share of 2025 value, because high-THC dried flower now makes up most new prescriptions. Medicinal Flower grows fastest at 7.27% a year, as sponsors launch new cultivars and patients move from oils to vaporized flower.

How do pain and mental health split demand?

Based on application, the market is categorized into pain management, mental health and sleep, neurological and supportive care, and nutrition and materials. Pain Management led with a 46.0% share of 2025 value, because chronic non-cancer pain accounts for roughly half of approvals. Mental Health and Sleep grows fastest at 7.38% a year, as more patients seek treatment for anxiety and insomnia.

Why do integrated platforms gain share?

Based on operating model, the market is categorized into integrated brand platforms, independent product sponsors and contract production networks. Integrated Brand Platforms led with a 47.0% share of 2025 value, because they control cultivation, brands, clinics and distribution. Integrated Brand Platforms grow fastest at 7.40% a year, as mergers and clinic acquisitions add scale. Contract production networks serve brands that do not own plants, which keeps them useful for new sponsors entering the market.

How do pharmacies reach prescribed patients?

Based on distribution channel, the market is categorized into community pharmacies, specialist dispensing pharmacies and hemp retail and trade. Community Pharmacies led with a 54.0% share of 2025 value, because most patients fill scripts close to home. Specialist Dispensing Pharmacies grows fastest at 7.08% a year, as online and specialist pharmacies serve telehealth patients across the country.

Prescriptions, quality rules and hemp investment lift sales

How does compliant prescription access support repeat demand?

Compliant prescription access supports repeat demand, because patients with an approval return for refills every month. Category B approvals under the Special Access Scheme rose from 57,711 in 2020 to 177,762 in 2024, according to a review of the regulatory process, which tripled the yearly flow of new approvals. Vitura Health also reported more than 375,000 consultations in fiscal 2025, with over 4,800 pharmacies and 2,700 doctors registered on its Canview platform. The company completed its acquisition of Candor Medical in February 2025, adding about 15,000 active clinic patients. As a result, community pharmacies hold 54.0% of 2025 value, and scripts flow through the wider retail pharmacy network.

Why do equivalent quality rules favor capable manufacturers?

Equivalent quality rules favor capable manufacturers, because domestic and imported products must meet the same national standards for medicinal products. ECS Botanics holds a national licence to manufacture GMP-certified products that are equivalent to PIC/S standards. Cannatrek operates one of the largest AU-GMP certified manufacturing facilities in Australia, according to the merged group's July 2026 presentation. More than 1,000 medicinal products are supplied in Australia, so buyers can compare quality across brands. Cannatrek also brought nine proprietary brands and 72 products into the merged group. In turn, sponsors with certified plants win contract work and pharmacy listings, while smaller importers face higher testing and compliance costs.

Download Free Sample

How does hemp processing investment widen demand?

Hemp processing investment widens demand, because new decorticating plants turn hemp stalks into fiber for building, textiles and packaging. Australian hemp plantings rose to 3,266 hectares in 2023-24, up from 1,493 hectares a year earlier, according to industry crop data. New South Wales planted about 2,000 hectares, above its earlier peak of 1,900 hectares. The country now has 11 decorticating facilities, compared with two five years earlier, after A$52 million of investment over three years. A further A$195 million of investment is expected over the next two years. As a result, industrial hemp products grow alongside medicinal sales, and growers also supply seed for hemp-based foods sold in supermarkets.

Why does an aging population raise pain treatment demand?

An aging population raises pain treatment demand, because chronic pain becomes more common with age. Australians aged 65 and over made up 18.1% of the population in 2025, up from 17.4% in 2023, according to the World Bank. About one in five Australians aged 45 and over live with chronic pain, based on national health data. Roughly half of medicinal approvals are for chronic pain not caused by cancer, which makes pain the largest single reason that doctors seek approval. In turn, pain management holds 46.0% of 2025 value, and older patients who cannot tolerate opioids keep asking doctors about plant-based options.

High-potency flower and consolidation reshape supply

How is the shift to high-potency flower changing supply?

The shift to high-potency flower is changing supply, because many patients now prefer vaporized dried flower over oils. High-potency THC products made up more than half of approvals in 2025, according to addiction researchers. ECS Botanics launched Gelonoidz #20, its first Australian-grown Terphogz flower, on June 22, 2026, with a 23% THC label claim and about 2.8% total terpenes. The company grows it under mixed light at Murrabit West in northwest Victoria and expects up to three Terphogz cultivars during fiscal 2027. As a result, medicinal flower grows fastest at 7.27% a year, and growers compete on genetics, potency and terpene profiles.

Why is the rise of integrated platforms notable?

The rise of integrated platforms is notable, because companies now join growing, brands, clinics and distribution under one owner. Little Green Pharma and Cannatrek completed their merger on June 1, 2026, creating LGP Cannatrek Group. The combined group holds 13 brands and 105 products, built from four LGP brands with 33 products and nine Cannatrek brands with 72 products. It also runs the MyQuest and MyEden clinics and the Greenship distribution business. Vitura Health also gained a patient base of nearly 30,000 through the Releaf assets of its Flora Holdings joint venture. In turn, integrated brand platforms grow fastest at 7.40% a year.

Download Free Sample

Can export markets open new demand for local producers?

Export markets can open new demand for local producers, because European medical programs are growing faster than Australian supply needs. LGP Cannatrek Group has exports or distribution agreements in more than 11 countries, including Germany, France, the U.K., Italy and Poland. Germany had nearly 900,000 medical patients, and the U.K. is expected to pass 140,000 patients by the end of 2026, according to the same presentation. The group also runs a Danish facility with 21,500 square meters of cultivation space. As a result, Australian growers with GMP plants can sell surplus flower abroad, which supports local capacity even when domestic prices fall.

Is there room to grow as quality standards tighten?

Compliant sponsors have room to grow as quality standards tighten, because stricter rules push weaker products out of the market. The national regulator received 790 submissions on its review of unapproved products and published its response on Feb. 20, 2026. That response points to education, clearer labeling, mandatory warnings and child-resistant closures for domestic and imported products. Health practitioner regulators also issued prescribing guidance on July 9, 2025, after finding that eight practitioners each wrote more than 10,000 scripts in six months, according to the Nursing and Midwifery Board of Australia. In turn, sponsors with clear labeling and clinical support can win pharmacy and prescriber trust.

Prescribing scrutiny, price pressure and evidence gaps weigh

How does prescribing scrutiny slow patient growth?

Prescribing scrutiny slows patient growth, because regulators now watch high-volume telehealth prescribing more closely. As a result, some clinics may cut short consultations and single-question assessments, which reduces new approvals. Companies respond with longer consultations, better records and clinical education, which keeps prescribers compliant while patients still reach treatment through telehealth and face-to-face clinics across the country. Many patients also fill scripts through online pharmacy services that check each prescription.

Why does price competition squeeze margins?

Price competition squeezes margins, because more than 1,000 products and hundreds of brands compete for the same patients. In turn, flower prices fall as growers and importers fight for pharmacy shelf space and prescriber attention. Companies respond with mergers, value ranges and premium cultivars, which help them hold patients across price tiers and spread fixed plant costs over larger volumes each year. Smaller sponsors without their own plants feel this pressure most.

How do evidence gaps limit prescriber uptake?

Evidence gaps limit prescriber uptake, because many products lack the large trials that support registered medicines. As a result, many doctors still decline to prescribe, and pain specialists urge caution with high-THC flower. Sponsors respond with observational studies, patient registries and clinical trials, which build the data that prescribers, payers and regulators need before supporting wider use in routine care. Such evidence will take years to build, so uptake by cautious prescribers will rise only slowly.

Why do hemp licensing costs slow farm uptake?

Hemp licensing costs slow farm uptake, because each state sets its own licence fees, testing rules and inspection charges. In turn, small growers face higher costs per hectare than large farms with processing contracts. Growers respond by forming cooperatives and signing supply deals with decorticating plants, which spread licensing and testing costs and give them a reliable buyer before planting each season. State governments have also reviewed licensing rules to make hemp farming simpler for new growers.

New South Wales and ACT lead as Queensland and NT rise

Why do new South Wales and the ACT hold the top share?

New South Wales and Australian Capital Territory held a 33.7% share of 2025 value and grow at 6.58% a year, because the zone had 9.16 million people in March 2026. Sydney hosts many telehealth clinics, specialist pharmacies and wholesalers, which keeps prescribing and dispensing activity high. New South Wales also planted about 2,000 hectares of hemp in 2023-24, the most of any state, and those crops feed industrial hemp processing for fiber and seed. As a result, the zone leads both medicinal and hemp demand.

How does Victoria support demand?

Victoria held a 23.0% share of 2025 value and grows at 6.88% a year, because Melbourne has a dense network of clinics, pharmacies and distribution centers. The state had 7.15 million people in March 2026 and grew 1.6% in a year. Victoria also hosts domestic cultivation, including mixed-light flower production in the northwest of the state. As a result, Victorian growers and sponsors supply patients both within the state and across the country.

Download Free Sample

Why are the western and southern states important?

Western Australia, South Australia and Tasmania held a 23.1% share of 2025 value and grow at 7.08% a year, because Western Australia had the fastest population growth of any state, at 2.1%. Perth also hosts craft indoor cultivation, while Tasmania has a long history of licensed hemp and poppy farming. In turn, the zone adds both prescribed patients and hemp supply as its population and farm licensing grow.

Why are Queensland and the Northern Territory growing fastest?

Queensland and Northern Territory held a 20.2% share of 2025 value and grow fastest at 7.28% a year, because Queensland grew 1.6% to 5.74 million people in the year to March 2026. Population growth in south-east Queensland adds new patients and pharmacies each year, and the state licenses hemp growers for seed and fiber.

Download Free Sample

Regulatory reviews, mergers and launches, 2025–2026

Indoor growing, GMP extraction and hemp processing advance

• Indoor and mixed-light cultivation controls light, temperature and humidity, which gives growers consistent THC and terpene levels in each harvest. Growers use it to produce premium flower for pharmacy shelves.
• GMP extraction and formulation turns flower into oils, capsules and cartridges with tested doses, which lets sponsors meet national manufacturing standards and supply export markets.
• Hemp decortication separates hemp stalks into long fiber and woody hurd, which opens markets in building materials, textiles and packaging for growers. Australia now has 11 decorticating facilities.

Integrated platforms compete with independent sponsors

Competition is led by integrated platforms that combine cultivation, brands, clinics and distribution, alongside independent sponsors that import or contract their products. LGP Cannatrek Group formed in June 2026 and holds 13 brands and 105 products, with MyQuest and MyEden clinics and the Greenship distribution business. Vitura Health runs the Canview platform, which links over 4,800 pharmacies and 2,700 doctors, and lists about 600 products from roughly 70 brands. ECS Botanics grows flower in northwest Victoria and holds a national GMP manufacturing licence. Montu, founded in 2019, runs the Alternaleaf patient service for Australian patients. Rivals compete on product range, potency, price, clinic reach and supply reliability. Because prices are falling, scale and certified manufacturing matter more each year.

Which companies supply Australian patients?

Credence Research view on medicinal and hemp demand

Credence Research's view is that the Australia legal cannabis market will keep growing because prescribed patients refill every month and new patients still join through telehealth clinics. Medicinal flower remains the largest value pool, while integrated platforms gain share through mergers. Tighter quality and prescribing rules will remove weaker products and clinics. Sponsors with certified plants, clear labeling, clinical support and export options should gain the most, while price competition keeps margins tight for smaller sponsors.

How the national medicinal and hemp estimate was built

The report uses 2025 as the base year on a calendar basis, and market values come from the Credence Research model. That model combines Special Access Scheme approval data, regulatory review documents, practitioner guidance, population statistics, hemp crop data and listed company disclosures. Segment splits and zone growth rates are Credence Research estimates, while zone shares follow the client-defined split. Sources used are official statistics, government and regulator publications, industry crop data and company filings, and no interviews or surveys were used.

Quality standards and exports carry growth to 2035

The Australia legal cannabis market is expected to reach USD 1.08 billion by 2035, a 6.91% CAGR during 2026–2035, as more patients use prescribed products for pain, sleep and mental health. Growth should be strongest in flower, mental health and integrated platforms, because patients prefer vaporized flower and companies keep consolidating. Hemp fiber and food add a smaller but steady stream of demand. Tighter rules may slow new approvals for a time, while exports could lift domestic production.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.